Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia

Experimental Hematology

Volumn 30, Issue 11, 2002, Pages 1302-1308

  Kasimir Bauer, Sabine ^a   Beelen, Dietrich ^a   Flasshove, Michael ^a   Noppeney, Richard ^a   Seeber, Siegfried ^a   Scheulen, Max Ernst ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 27; IDARUBICIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CYTARABINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENES, BCL-2; GENES, MDR; GENES, P53; HEAT-SHOCK PROTEINS; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036841651     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)00926-8     Document Type: Article

References (30)

1. Durrieu F., Belaud-Rotureau M.A., Lacombe F.et al. Synthesis of bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic cell lines. Cytometry. 36:1999;140.
2. Wuchter C., Karawajew L., Ruppert V.et al. Clinical significance of CD95, bcl-2 and bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia. 13:1999;1943.
3. Nakano Y., Naoe T., Kiyoi H.et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol. 65:2000;23.
4. Sonneveld P. Multidrug resistance in haematological malignancies. J Int Med. 247:2000;521.
5. Legrand O., Simonin G., Beauchamp-Nicoud A., Zittoun R., Marie J.P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood. 94:1999;1046.
6. Leith C.P., Kopecky K.J., Chen I.M.et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood. 94:1999;1086.
7. Tsimberidou A.M., Paterakis G., Androutsos G.et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res. 26:2002;143.
8. Broxterman H.J., Sonneveld P., Pieters R.et al. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia. 13:1999;258.
9. Kasimir-Bauer S., Ottinger H., Meusers P.et al. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive for the response to induction chemotherapy. Exp Hematol. 26:1998;1111.
10. Flasshove M., Meusers P., Schütte J.et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann Hematol. 79:2000;533.
11. Berman E., Heller G., Santorsa J.et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 77:1991;1666.
12. Cheson B.D., Cassileth P.A., Head D.R.et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 8:1990;813.
13. Becher R., Carbonell F., Bartram C.R. Isochromosomes 17q in Ph1-negative leukemia. a clinical, cytogenetic, and molecular study Blood. 75:1990;1679.
14. Hamada H., Tsuruo T. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A. 83:1986;7785.
15. Lehne G., De Angelis P., Clausen O.P.F., Egeland T., Tsuruo T., Rugstad H.E. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene. Cytometry. 20:1995;228.
16. Flens M.J., Izquierdo M.A., Scheffer G.L.et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 54:1994;4557.
17. Akbar A.N., Borthwick N., Salmon N.et al. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med. 178:1993;427.
18. Borg A., Lennerstrand J., Stenmark-Askmalm M.et al. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer. 71:1995;1013.
19. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc B. 34:1972;187.
20. Harrell F.E. The PHGLM procedure. In. Supplemental library user's guide:1983;SAS Institute, Cary, NC. 267p.
21. Slovak M.L., Kopecky K.J., Cassileth P.A.et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia. a Southwest Oncology Group/Eastern Cooperative Oncology Group study Blood. 96:2000;4075.
22. Preisler H., Davis R.B., Kirshner J.et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia. a Cancer and Leukemia Group B study Blood. 69:1987;1441.
23. Mayer R.J., Davis R.B., Schiffer C.A.et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 331:1994;896.
24. Berman E., McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood. 79:1992;3267.
25. Tolomeo M., Gancitano R.A., Musso M.et al. Comparative activity of idarubicin and idarubicinol in combination with cyclosporine A in multidrug-resistant leukemia cells. Cancer Chemother Pharmacol. 39:1996;157.
26. Scheulen M.E., Müller M., Schröder J.et al. Correlation of cellular pharmacokinetics of idarubicin and idarubicinol, P-glycoprotein expression and response in patients with acute myeloid leukemia. Proc Am Assoc Cancer Res. 35:1994;428.
27. Broxterman H.J., Sonneveld P., van Putten W.J.L.et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia. 14:2000;1018.
28. Borg A.G., Burgess R., Green L.M., Scheper R.J., Yin J.A.L. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukemic cells. Br J Haematol. 108:2000;48.
29. Baer M.R., Swann V.L., Strollo M.M.et al. Frequent coexistence of multiple mechanisms of multidrug resistance in acute myeloid leukemia cells. Blood. 90:1997;181a.
30. Van der Kolk D.M., de Vries E.G.E., van Putten W.L.J.et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res. 6:2000;3205.